Retension Insiders Buy 30,800 Shares
16 sourcesUpdated Oct 14, 20261 min read
Sponsored
Retension Pharmaceuticals CEO Eric Keller bought 20,800 shares for $249,600, increasing his stake by 5.17%, while director Franklin Berger purchased 10,000 shares for $120,000. Both transactions were made at $12 per share on October 13 and disclosed in SEC filings. Retension is a clinical-stage company developing treatments for hypertension and other cardiovascular diseases.
Sponsored
How it spread
Broke tradingview.com · Oct 12, 6:19 PM ET16 sources +25h on
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?
Sponsored
